Introduction
In patients without a human leukocyte antigen (HLA)-matched sibling donor-unrelated donor HSCT (UD-HSCT) is increasingly used. 1, 2 Mortality and morbidity after UD-HSCT owing to graft-versus-host disease (GVHD) and related complications remains a major problem. The incidence of severe GVHD as well as graft failure in matched UD-HSCT is higher than in HLAidentical sibling transplantation. 3, 4 Historically, donor selection was based on serological methods. It soon became evident that a significant number of serologically HLA-A, -B, -DR-identical donor-recipient pairs do have HLA disparities at the allele (genotypical) level. [5] [6] [7] This has led to the replacement of serological methods by molecular typing and with further technological progress by high-resolution typing. [8] [9] [10] [11] High-resolution matching is carried out for the HLA-A, -B and -DRB1 loci while the significance, if any, of other loci, especially HLA-C, HLA-DQ or HLA-DRB3 or DRB5, is less clear. Some centers consider a 6/6 matched (A/B/DR) donor-recipient pair a 'match', whereas others require 8/8 (A/B/DR/DQ) or 10/10 (A/B/C/DR/DQ) matching. The chance of finding a 10/10 matched donor is lower than finding a 5/6 or 6/6 matched donor and the clinician is often faced with the decision to continue the search or accept a mismatch. Presently, it is not known whether any mismatches, and if so, of what type, and on which loci, result in acceptable outcome in the context of the patient's disease status. 4, 5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Other factors, such as cytomegalovirus (CMV) serostatus, GVHD prophylaxis, stem cell dose and source, donor or patient age, diagnosis and remission status influence the incidence of GVHD and outcome of UD-HSCT. 13, [22] [23] [24] We report here the outcome of all 214 consecutive UD-HSCT typed by high-resolution technology at the Swiss National Reference Laboratory for Histocompatibility (LNRH).
Design and methods

Patients
Between 1990 and 2003 (since the creation of the Swiss National Donor Registry), 214 consecutive patients underwent allogeneic stem cell transplantation from an unrelated donor in Switzerland. The median follow-up of surviving patients was 32 months.
The stem cell source was bone marrow (BM) in 154 (72%) and mobilized peripheral blood in 60 (28%). Recipients of cord blood were excluded because HLA mismatches may impact differently in this patient population (n ¼ 3). The median age was 29 years (range 1-61 years). Details of the study population are outlined in Table 1 . The study was approved by the respective Institutional Review Boards.
HLA typing and matching
All donors and recipients were typed for HLA-A, -B, -C, -DRB1/B3/B5 and -DQB1 by high-resolution molecular typing with polymerase chain reaction (PCR)-sequencespecific primers, PCR-sequence-specific oligonucleotide probes hybridization 25 and direct sequencing at the Swiss National Reference Laboratory for Histocompatibility.
Based on high-resolution typing (four-digit level), 130 donor-recipient combinations were 10/10 matches, 69 were 9/10 matches and 15 were p8/10 matches ( Figure 1 , Supplementary Information). Except for three patients with an antigen mismatch (two-digit level), all other HLA-A/-B/-DRB1 mismatches were allele mismatches (detectable by four-digit typing only). In six patient-donor pairs, the HLA disparity was observed in the rejection direction only (three HLA-DQB1, one HLA-DRB3 and two HLA-C). The distribution of single mismatches was as follows: 10 HLA-A or -B, 29 HLA-C, eight HLA-DRB1, six HLA-DRB3 and 16 HLA-DQB1. Of the 15 pairs with multiple mismatches, 14 were 8/10 matches and one pair was a 7/ 10 match. As observed in previous studies, 5, 10, 11 HLA-C incompatibilities accounted for the largest number of mismatches, representing 42% of the 69 one-allele mismatches. For transplants performed after 1997, most of the HLA incompatibilities were known at the time of transplant. In patients transplanted before 1997, mismatches were identified on stored samples and were hence unknown at the time of transplant.
Killer immunoglobulin-like receptor (KIR) incompatibilities were analyzed on the basis of the presence/absence of HLA-C Lys80 and HLA-C Ans80 epitopes recognized by the KIRs, 26 ,27 as determined from allele-level typing data of 29 pairs with C mismatches only. The KIR ligand-mismatched group comprised seven pairs in which the recipient lacks KIR mismatch in the donor (i.e. patient Asn80/Asn80 and donor Asn80/Lys80), and nine pairs in which the donor lacks KIR ligand in the recipient (total: 16 pairs). No KIRligand mismatches were observed in the remaining 13 pairs.
Because of small numbers, we pooled groups according to similarities in outcome. For final comparisons, the groups with HLA-A/-B/-DRB1/multiple mismatches (n ¼ 33), the group with HLA-C (n ¼ 29) and the group with HLA-DQ/ -DRB3 mismatches (n ¼ 22) are compared to the group of 10/10 allele-matched donor-recipient pairs (n ¼ 130).
Transplantation procedures
Conditioning regimen was of standard intensity (cyclophosphamide (Cy) þ total body irradiation or BuCy), or of reduced intensity (29 patients). Graft-versus-host disease prophylaxis was based on cyclosporin A (CSA) with or without methotrexate (MTX) or other drugs such as mycophenolate mofetil, or based on antithymoglobulin (ATG) þ CSA, or by T-cell depletion in 93, 67 and 52 patients, respectively. Acute GVHD was graded according to the standard criteria 28 in patients surviving 421 days post transplantation. The occurrence of chronic GVHD (cGVHD) was evaluated in patients surviving 4100 days after transplantation.
Clinical end points
The primary end points of this study was overall survival (OS) defined as the time to death, surviving patients being censored at last contact and the cumulative incidence of treatment-related mortality (TRM) defined as the time to death without relapse. Secondary end points included neutrophil engraftment, defined as the first of 3 consecutive days with a neutrophil count 40.5 Â 10 9 /l, the cumulative incidence of grades II-IV acute GVHD (aGVHD) and the proportion of patients surviving 4100 days with cGVHD and the cumulative incidence of relapse in patients with malignant disease. Primary non-engraftment was defined as the absence of neutrophil recovery in patients surviving more than 21 days after transplantation. Graft rejection was defined as graft loss determined by chimerism testing after initial engraftment.
Statistical analysis
Characteristics of patients were compared using the w 2 or Kruskall-Wallis tests, where appropriate. The productlimit method of Kaplan and Meier was used to estimate survival; 29 the cumulative incidence, with death from other causes treated as competing events, was used for engraftment, aGVHD, relapse and TRM. 30 Comparisons among groups was by the log-rank test. The Cox proportionalhazard regression model was used for multivariate analysis of survival, TRM and relapse. 31 Variables considered were HLA match, patient age, donor-recipient sex match, disease and disease stage, conditioning intensity, GVHD prophylaxis, CMV serology in the donor and recipient, year of transplant and transplant center.
Results
Patient characteristics by degree of HLA matching are shown in Table 1 . There were no significant differences High-resolution matching in unrelated donor HSCT Y Chalandon et al between the groups regarding donor-recipient sex, type of disease, disease stage (in patients with malignancy), year of transplant, stem cell source, GVHD prophylaxis, conditioning regimen intensity and CMV serostatus. There was a trend for younger age in the group with HLA-A/-B/ -DRB1/multiple loci mismatches and the group with HLA-C mismatch (P ¼ 0.11) and a trend for longer waiting time between diagnosis to transplant in the group with HLA-A/ -B/-DRB1/multiple loci mismatches (P ¼ 0.19).
The 3-year survival probability of the entire population was 4578%. Univariate estimates are shown in Table 2 and Figure 2 . Human leukocyte antigen matching was the most significant factor associated with mortality in multivariate analysis; mortality risks in patients with HLA-A/ -B/-DRB1/multiple loci mismatches were 4.71 (95% confidence interval (CI) 2.9-7.65), 2.33 (1.24-4.35) in patients with HLA-C mismatch and 1.22 (0.61-2.43) in patients with HLA-DQB1/-DRB3 mismatches as compared to (25) 35 (27) 4 (12) 7 (24) 7 (32) ALL 36 (17) 17 (13) 11 (33) 6 (21) 2 (9) MDS/MPS 31 (14) 20 (15) 5 (15) 1 (3) 5 (23) Lymphoid neoplasia 14 (7) 6 (5) 3 (9) 3 (10) 2 (9) High-resolution matching in unrelated donor HSCT Y Chalandon et al recipients of 10/10 HLA-matched transplants (Table 3) . In more detail: survival probabilities in mismatched transplants were in decreasing order 67740% with a DRB3 mismatch (n ¼ 6), 46726% with DQB1 mismatch (n ¼ 16), 44720% with HLA-C mismatch (n ¼ 29), 13717% with multiple mismatches (n ¼ 15) and 0% with HLA-A or B mismatch (n ¼ 10), and 0% with DRB1 mismatches (n ¼ 8).
HLA-C mismatches were further subdivided according to whether or not they represented a KIR mismatch. There were seven donor-recipient pairs with a KIR-ligand mismatch in GVHD direction and 22 without. These patients did not differ in survival, 35722 vs 50740% in patients without and with a KIR mismatch, respectively. When limiting the analysis to the subset of patients with myeloid malignancy (acute myeloid leukemia, chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative syndrome (MPS)), differences were more marked (22726 vs 100%, P ¼ 0.06).
Three-year OS was 44710 and 49711% in patients transplanted between 1990-1999 and 2000-2004, (P ¼ 0.2). There was a tendency for lower 3-year OS in patients with MDS/MPS (24718%) and higher 3-year OS for patients with CML and congenital disease (59713 and 67738%, respectively) (P ¼ 0.42). Conditioning regimen intensity, time from diagnosis to transplantation and donor-recipient sex matching was not associated with survival. CMVnegative donors for CMV-positive patients had poorer survival than other CMV serology combinations. Significant differences in survival were found in patients receiving GVHD prophylaxis with ATG as compared to T-cell patient/donor pairs. Among the 67 combinations with a 9/10 match, all incompatibilities were bidirectional, except four pairs with a mismatch in rejection direction only and two pairs with a mismatch in GVH direction only. Three of the 29 pairs with a C-locus mismatch were incompatible for both alleles. Operationally, the two pairs with a DRB1 þ DRB3 mismatch were counted as DRB1 single-locus mismatches only. Among the 17 pairs with a X8/10 match, two incompatibilities were in the rejection and one in the GVH direction only. Four of seven single B-locus mismatches were owing to B35 allele disparities, 3/6 single DRB1 mismatches concerned DR11 allele disparities and 6/16 DQB1 mismatches resulted from DQB1*0302 vs 0202 alleles linked to DR7 haplotypes. Only 1/16 DQB1 disparities resulted form the DQB1*0301 vs 0302 mismatch known to be negative in MLC tests. Similarly, 3/29 single C-locus mismatches concerned the Cw*0303 vs 0304 incompatibility associated with a negative or weakly positive CTLp assay. 25 See also full descriptive table in supplementary information on the web-site. High-resolution matching in unrelated donor HSCT Y Chalandon et al depletion or CSA þ MTX (P ¼ 0.027) and in patients older than 40 years of age compared to younger patients (P ¼ 0.003). The 3-year cumulative incidence of TRM is shown in Figure 3 , and Tables 2 and 3 . Treatment-related mortality in matched donor-recipient pairs was 27% (95% CI 20-36%). Treatment-related mortality risks were significantly higher in recipients of HLA-A/-B/-DRB1/multiple locimismatched transplants (relative risk (RR): 3.56 (1.96-6.47)) and in recipients of transplants mismatched for HLA-C (RR: 2.79 (1.41-5.50)), but not in recipients of HLA-DQB1/DRB3-mismatched transplants (RR: 1.06 (0.44-2.55)). Other variables impacting on TRM in multivariate analysis were GVHD prophylaxis, with lower TRM with ATG or T-cell depletion (P ¼ 0.09), age, with lower TRM in younger patients (o40 years) (P ¼ 0.006) and transplants carried out after 2000 (P ¼ 0.041).
Relapse incidence and risks are shown in Tables 2 and 3 . The cumulative incidence of relapse in patients with malignant disease receiving a 10/10 matched transplant was 17 (11-26)%. Relapse risks were higher in recipients of HLA-A/-B/-DRB1/multiple loci-mismatched transplants (RR: 6.79 (3.13-14.71)) but not in recipients of transplants mismatched for HLA-C (RR: 1.1 (0.3-3.99)) and mismatched for HLA-DQB1/DRB3 (RR: 2.08 (0.76-5.70). In multivariate analysis, there was a higher risk of relapse in patients 440 year of age (P ¼ 0.027) and in patients with advanced disease stage (P ¼ 0.005).
The cumulative incidence of severe aGVHD (grades III-IV) was higher in recipients of HLA-A/-B/-DRB1/multiple loci-mismatched transplants as compared to recipients of 10/10 HLA-matched transplants ( Table 2 ). Recipients of HLA-C-or HLA-DQB1/DRB3-mismatched transplants did not have higher incidences than recipients of matched transplants.
There were no significant differences in the proportion of patients surviving 4 100 days with cGVHD among the different HLA-matching groups (Table 2) .
HLA matching did not influence the time to engraftment, P ¼ 0.8 by log-rank test (Table 2) . One patient had primary non-engraftment. Three patients had secondary graft failure, two after standard intensity and one after reducedintensity conditioning. Time to neutrophil engraftment was 17 days (median, 95% CI 16-18). Two patients were not eligible because of early death on days þ 3 and þ 18, respectively.
Discussion
In this cohort study of donor-recipient pairs with highresolution HLA typing for 10 loci, we found a highly significant impact of HLA matching on outcome. Because donors had been selected for HLA-A/B/DR compatibility by low-resolution typing, all but three disparities were allele (four-digit) and not antigen (two-digit) mismatches. We grouped mismatches for HLA-A/-B/-DRB1/and multiple loci and mismatches for -DQB1 and -DRB3 into three separate groups based on similarities in outcome. The final analysis therefore compares three groups, transplants mismatched for HLA-A/-B/-DRB1/ and multiple loci, transplants with HLA-C mismatch and transplants with mismatches for -DQB1 and -DRB3 to transplants matched for 10/10 alleles. Human leukocyte antigen-A/-B/-DRB1/ multiple loci-mismatched transplants were associated with low survival probabilities. Recipients of transplants mismatched at HLA-C had better survival than recipients of transplants mismatched at HLA-A/-B/-DRB1/multiple loci. Human leukocyte antigen-DQB1 and -DRB3 incom- Abbreviations: CI ¼ confidence interval; TRM ¼ treatment-related mortality. Adjusted for GVHD prophylaxis, CMV serostatus, disease and disease stage and age in models of survival, for GVHD prophylaxis, age and year of transplant in models of TRM and for age, disease and disease stage in models of relapse. High-resolution matching in unrelated donor HSCT Y Chalandon et al patibilities appeared not to be associated significantly with mortality compared to 10/10 matched transplants. Mismatches affected TRM and relapse differently, with mismatches at the HLA-C locus being associated with higher TRM but similar relapse risks as compared to transplants from matched donors, whereas HLA-A/-B/ -DRB1/multiple loci-mismatched transplants resulted in high rates of TRM and relapse. These differences may be owing to differential effects of mismatches of particular loci on GVL and GVHD, they may reflect higher intensities of immunosuppression in recipients of mismatched transplants or they may reflect patient selection. Patients receiving mismatched transplants did not have more advanced disease compared to recipients of matched transplants. Our observations concord with the hypothesis that mismatches at some loci are better tolerated than others. This could be due in part to their level of expression at the cell surface. For instance, HLA-C and -DQ, expressed at lower levels, seem to impact less on survival than mismatches for HLA-A, -B or -DRB1. 32 Differences between matched and mismatched transplants, as shown here, exceed differences commonly reported in the literature. This may be owing to small patient numbers in each group, or owing to patients at higher risks based on some unmeasured factor, being more likely to receive mismatched transplants. On the other hand, large multicenter studies showing small effects of HLA disparities may underestimate the impact of mismatching owing to interlaboratory variability and heterogeneity in HLA typing quality.
There is little consensus on what constitutes an acceptable mismatch. This is of importance when it comes to donor selection in the absence of a fully matched donor; choices have to be made with regard to accepting a mismatched donor, looking for other sources of stem cells (such as cord blood) or a haploidentical donor, or avoiding HSCT altogether.
The literature on the impact of specific loci on outcome is heterogeneous. A large study of 1874 donor-recipient pairs in the National Marrow Donor Program (NMDP) did not find a differential effect of mismatches at specific loci on outcome. 11 In a large Seattle study on 948 patients, the association of mortality with HLA-A/-B/-C/-DRB1/ -DQB1 mismatches was seen mainly in low-risk patients, particularly in patients with early CML, but not in patients with more advanced disease. 33 The Japan Marrow Donor Program (JMDP) studies did not find a lower survival in patients mismatched for HLA-C or class II, but only with HLA-A 5 and -B 21 mismatches. The discrepancy between the Japanese and the North American or European studies may reflect disparities in the HLA and non-HLA genetic backgrounds of the more homogenous Japanese population compared to the more heterogenous Caucasoid populations. 34 Similarly, other studies have ascribed differences in GVHD incidence between ethnicities (Japanese vs Caucasoid) to genetic disparities as pointed out recently by Oh et al. 35 in the HLA-identical sibling transplant setting. A recently published German study found no difference in outcome between patients with class I allele mismatches and patients receiving matched transplants, which is in contrast to most of the data reported in other North American 11, 33 and European studies. 32, 36 The authors ascribed their findings to racial homogeneity 37 and to the use of gut decontamination and strict isolation possibly diminishing GVHD. Confirming two previous reports, 5, 11 we did not find any negative impact of HLA-DQ and -DRB3 mismatching on transplant outcome. There was no skewing towards DQ incompatibilities perceived to be more clinically permissible such as DQB1*0301 vs *0302.
Therefore, when comparing survival probabilities, there is a wide range of published results spanning from no, or close to no effect of HLA-disparities to large differences for some or all mismatched loci.
Higher relapse risks in patients with transplants mismatched at HLA-A/-B/-DRB1/multiple loci may be explained by patient selection, mismatched transplants being more readily accepted in patients with inherently higher relapse risks or by the absence of GVL in mismatched transplants. We carefully analyzed whether patients with mismatches were at higher risk, that is, more severe disease, or more advanced disease stage and could not find any difference between the high-risk and the lowrisk groups. We cannot exclude, however, that recipients of mismatched transplants had some unmeasured risk factors for relapse. The low relapse rate associated with HLA-C mismatches in this study is concordant with data from the JMDP study showing a decreased risk of relapse of patients with an HLA-C mismatch. 5 It has been shown that KIR negatively regulate natural killer cells recognizing HLA-C allotypes. 38 A beneficial effect of a KIR-ligand mismatch has been shown in HSCT from haploidentical donors, 26 but are more controversial in transplants from unrelated donors. 27, 39 In the small group of patients with a single HLA-C mismatch, KIR-ligand mismatching impacted on outcome, but this was not significant and was restricted to patients with myeloid malignancy.
Recipients of transplants mismatched for HLA-A/-B/ -DRB1/multiple loci had higher risks of aGVHD than other groups. We found no impact of HLA incompatibilities on cGVHD. The absence of a correlation of HLA mismatches with cGVHD in our study might be owing to the large proportion of patients receiving either transplants depleted in vitro of T cell or ATG as GVHD prophylaxis, which provides some degree of in vivo T-cell depletion. Patients receiving T-cell-depleted transplants are at higher risks of infectious complications.
This study has several limitations; the patient sample is small and heterogenous, and transplant protocols were not uniform. Results should therefore be interpreted cautiously. The strength of this study lies in the HLA typing carried out by a single reference laboratory, thus assuring typing quality with equal level of resolution, and in the study design allowing for inclusion of all consecutive patients with transplants mediated by the Swiss BM donor registry, thus reflecting daily clinical practice and common donor selection logistics.
We found a graded decrease in long-term survival probabilities in recipients of unrelated donor transplants with best results with transplants from donor matched for HLA-A, -B, -C, -DR and DQ (10/10) by high-resolution typing. Results from donors with single mismatches at HLA-DQB1 or -DRB3 were comparable to 10/10 matched donors, mismatches at HLA-C being intermediate and mismatches at HLA-A/-B/-DRB1/multiple loci resulting in poor survival. If mismatches at the HLA-DQ/-DRB3 and HLA-C were considered to be acceptable, the donor pool would increase by 24%.
These results suggest that single-allele mismatches should not be treated equally. Larger studies will have to dissect out more clearly the magnitude of the risk incurred with specific mismatches. Without a suitable donor, alternative methods to unrelated donor HSCT should be considered.
